Characteristics of Patients and Response to Induction Treatment in Pro-B ALL Subtypes According to Cytogenetic and Molecular Analyses
| Characteristic . | t(4;11) and/or MLL-AF-4 Rearrangement N = 22 (%) . | Normal Karyotype or Other Cytogenetic Abnormalities N = 13 (%) . | P Value3-150 . | Cytogenetic and Molecular Analyses Not Available N = 22 (%) . |
|---|---|---|---|---|
| Sex | ||||
| Male | 14 (64) | 5 (38) | NS | 8 (36) |
| Female | 8 (36) | 8 (62) | 14 (64) | |
| Age (yr) | ||||
| Median (range) | 29 (22-62) | 39 (16-59) | NS | 33 (16-62) |
| ≤20 | 0 | 3 (23) | 5 (23) | |
| 21-50 | 19 (86) | 5 (38) | .007 | 11 (50) |
| >50 | 3 (14) | 5 (38) | 6 (27) | |
| Bleeding | 12 (55) | 3 (23) | NS | 6 (27) |
| Infection | 1 (5) | 5 (38) | .01 | 5 (23) |
| Peripheral lymph nodes | 10 (45) | 5 (38) | NS | 11 (50) |
| Hepatomegaly | 9 (41) | 6 (46) | NS | 7 (32) |
| Splenomegaly | 13 (59) | 5 (38) | NS | 6 (27) |
| CNS involvement | 2 (9) | 1 (8) | NS | 1 (5) |
| Mediastinal mass | 0 | 0 | 2 (9) | |
| WBC (×109/L) | ||||
| Median (range) | 168.3 (0.8-562.0) | 30.6 (5.2-545.0) | NS | 16.1 (0.5-489.0) |
| ≤30 | 6 (27) | 6 (46) | NS | 16 (73) |
| >30 | 16 (73) | 7 (54) | 6 (27) | |
| Hb (g/dL) | ||||
| ≤8 | 10 (45) | 6 (46) | NS | 10 (45) |
| >8 | 12 (55) | 7 (54) | 12 (55) | |
| Coexpression of myeloid antigens3-151 | ||||
| CD13 | 0 | 3 (27) | NA | 2 (16) |
| CD33 | 0 | 4 (36) | NA | 3 (18) |
| CD65s | 14 (64) | 3 (25) | .03 | 7 (32) |
| CR rate | 17 (77) | 11 (85) | NS | 14 (64) |
| Characteristic . | t(4;11) and/or MLL-AF-4 Rearrangement N = 22 (%) . | Normal Karyotype or Other Cytogenetic Abnormalities N = 13 (%) . | P Value3-150 . | Cytogenetic and Molecular Analyses Not Available N = 22 (%) . |
|---|---|---|---|---|
| Sex | ||||
| Male | 14 (64) | 5 (38) | NS | 8 (36) |
| Female | 8 (36) | 8 (62) | 14 (64) | |
| Age (yr) | ||||
| Median (range) | 29 (22-62) | 39 (16-59) | NS | 33 (16-62) |
| ≤20 | 0 | 3 (23) | 5 (23) | |
| 21-50 | 19 (86) | 5 (38) | .007 | 11 (50) |
| >50 | 3 (14) | 5 (38) | 6 (27) | |
| Bleeding | 12 (55) | 3 (23) | NS | 6 (27) |
| Infection | 1 (5) | 5 (38) | .01 | 5 (23) |
| Peripheral lymph nodes | 10 (45) | 5 (38) | NS | 11 (50) |
| Hepatomegaly | 9 (41) | 6 (46) | NS | 7 (32) |
| Splenomegaly | 13 (59) | 5 (38) | NS | 6 (27) |
| CNS involvement | 2 (9) | 1 (8) | NS | 1 (5) |
| Mediastinal mass | 0 | 0 | 2 (9) | |
| WBC (×109/L) | ||||
| Median (range) | 168.3 (0.8-562.0) | 30.6 (5.2-545.0) | NS | 16.1 (0.5-489.0) |
| ≤30 | 6 (27) | 6 (46) | NS | 16 (73) |
| >30 | 16 (73) | 7 (54) | 6 (27) | |
| Hb (g/dL) | ||||
| ≤8 | 10 (45) | 6 (46) | NS | 10 (45) |
| >8 | 12 (55) | 7 (54) | 12 (55) | |
| Coexpression of myeloid antigens3-151 | ||||
| CD13 | 0 | 3 (27) | NA | 2 (16) |
| CD33 | 0 | 4 (36) | NA | 3 (18) |
| CD65s | 14 (64) | 3 (25) | .03 | 7 (32) |
| CR rate | 17 (77) | 11 (85) | NS | 14 (64) |
Abbreviations: NS, not significant; NA, not applicable.
P values refer to the comparison between patients with a t(4;11) and/or MLL-AF-4 rearrangement versus patients with a normal karyotype or other cytogenetic abnormalities.
Missing data for 8 patients (CD13), 6 patients (CD33), and 1 patient (CD65s), respectively.